Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Advanced or recurrent endometrial cancer, drawn from the whole corpus: 25 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
What to give after progression on first-line immunotherapy.
The small benefit and real toxicity of immunotherapy in proficient tumours.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Rising mortality, especially among Black women in the United States, that new drugs have not yet reversed.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 14 changes by month →When this page itself was last checked or edited.
Primary PFS endpoint not met; mPFS 12.
A milestone in how this cancer is treated.
ORR 55.
A milestone in how this cancer is treated.
Endometrial ORR 57.